ASCENDO is a clinical-stage new drug company that focuses on development of first-in-class therapies for solid tumors and autoimmune diseases through innate immune regulations. The lead product ASD141 is a novel, innate immune checkpoint inhibitor that commands the innate immune system to coordinate a renewed attack on solid tumors. In pre-clinical studies, ASD141 showed promising anti-tumor activities in humanized mouse models when used alone or in combination with anti-PD1 or anti-CTLA-4 antibodies.